<DOC>
	<DOC>NCT01032291</DOC>
	<brief_summary>The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1. Metastatic colorectal adenocarcinoma. 2. Confirmed KRAS mutant tumor 3. Disease progression on oxaliplatin AND irinotecancontaining regimens, with at least one of these regimens containing bevacizumab. 4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. 1. Use of chemotherapy, hormonal therapy, immunotherapy or any other cancer or experimental treatment ≤ 28 days prior to the first day of the first cycle. 2. Radiotherapy for up to ≥ 30% of the bone marrow. 3. Surgery ≤ 28 days before day 1 of the first cycle (minimally invasive interventions for diagnostic purposes or disease staging are permitted). 4. Previous treatment with cetuximab, panitumumab, pomalidomide (CC4047), lenalidomide or thalidomide. 5. Untreated, symptomatic brain metastases (brain imaging not required). 6. Venous thromboembolism ≤ 6 months before day1 of the first cycle. 7. Current congestive heart failure (classes II to IV of the New York Heart Association). 8. Myocardial infarction ≤ 12 months before day1 of the first cycle. 9. Uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>KRAS</keyword>
</DOC>